Alembic Pharma Received Approval for Generic Methotrexate Injection

Alembic Pharmaceuticals has secured a key USFDA approval for its generic Methotrexate injection, marking another step in its expansion in the United States market.

The approval, granted by the US Food and Drug Administration, allows the company to market the drug in multiple strengths, strengthening its position in the high-value injectable segment.

The approved product is a generic Methotrexate injection, used in the treatment of several cancers and autoimmune disorders.

It will be available in 50 mg/2 mL multi-dose vials and 1 g/40 mL single-dose vials. The drug is widely prescribed for conditions such as leukemia, breast cancer, and rheumatoid arthritis, making it a critical addition to Alembic’s portfolio.

Also Read: How Digital Maturity is Powering Pharma's GMP Evolution

This Alembic Pharma USFDA approval came through the abbreviated new drug application pathway, confirming that the product is therapeutically equivalent to the reference listed drug. Such approvals are crucial for companies looking to scale in the competitive US generics market, where regulatory compliance and product quality are closely monitored.

The development highlights Alembic’s continued focus on complex generics and injectable therapies, segments known for higher entry barriers and better margins. With demand for oncology and specialty treatments rising, the approval positions the company to tap into a steady and large patient base.

Alembic Pharmaceuticals has been steadily building its pipeline of USFDA-cleared products, and this latest nod reflects its strategy to expand beyond conventional generics. By strengthening its injectable portfolio, the company is aiming to enhance both revenue potential and its presence in regulated global markets.